文献速递免疫规划

分泌型分支酸变位酶(Rv1885c)联合乙型肝炎病毒(HBV)衍生肽Poly6与铝佐剂疫苗接种抗结核保护作用

Protection against tuberculosis by vaccination of secreted chorismate mutase (Rv1885c) combined with a hepatitis B virus (HBV)-derived peptide, Poly6, and alum adjuvants.
PubMed 文献 · Vaccine · 2025-01-08

研究构建由结核分泌型分支酸变位酶(TBCM,Rv1885c)、乙型肝炎病毒衍生肽Poly6及铝佐剂组成的新型结核亚单位疫苗,在小鼠体内评估免疫原性、保护效力与治疗效力;结果显示TBCM联合Poly6及铝佐剂可诱导更强抗原特异性免疫应答,有效保护小鼠抵抗结核分枝杆菌K株感染,并降低已感染小鼠的细菌载量与肺部炎症。

要点

  • TBCM联合Poly6诱导的抗原特异性体液与细胞免疫应答强于单用TBCM或TBCM联合铝佐剂。
  • TBCM联合Poly6及铝佐剂可有效保护小鼠抵抗结核分枝杆菌K株感染。
  • 该疫苗平台在已感染强毒力Mtb K株小鼠中显著降低细菌载量与肺部炎症。

核心结论

  • TBCM在小鼠中具有高免疫原性,TBCM联合Poly6及铝佐剂是用于结核预防和治疗的潜有力疫苗平台。

研究设计与样本

  • 研究构建含TBCM(Rv1885c)、HBV衍生肽Poly6及铝佐剂(含或不含)的新型结核亚单位疫苗,并在小鼠体内模型评估免疫原性、保护效力与治疗效力。

主要发现

  • 皮下接种TBCM联合Poly6诱导的抗原特异性体液与细胞免疫应答强于单用TBCM或TBCM联合铝佐剂。
  • 在TBCM联合Poly6基础上加入铝佐剂可显著增强抗原特异性免疫应答。
  • 皮下接种TBCM联合Poly6及铝佐剂有效保护小鼠抵抗结核分枝杆菌K株感染。
  • 该疫苗平台在先前感染强毒力Mtb K株的小鼠中显著降低细菌载量与肺部炎症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis (TB) remains a significant global health issue due to the limited efficacy of the Bacillus Calmette-Guérin (BCG) vaccine, highlighting the need for the development of an improved TB vaccine. In this study, we created a novel TB subunit vaccine consisting of TB-secreted chorismate mutase (TBCM) (Rv1885c) and a hepatitis B virus (HBV)-derived peptide (Poly6), which elicits Type I interferon responses, both with and without an alum adjuvant. We evaluated the immunogenicity, protective efficacy, and therapeutic efficacy of this vaccine candidate in an in vivo mouse model. Our results revealed that subcutaneous vaccination with TBCM combined with Poly6 induced stronger antigen-specific humoral and cell-mediated immune responses than TBCM alone or TBCM combined with alum adjuvant. Furthermore, adding the alum adjuvant to TBCM combined with Poly6 significantly enhanced antigen-specific immune responses. Subcutaneous vaccination with TBCM combined with both Poly6 and alum adjuvants effectively protected mice against Mycobacterium tuberculosis (Mtb) K strain infection, demonstrating its potential as a TB vaccine. Additionally, this vaccine platform exhibited therapeutic potential by significantly reducing bacterial loads and lung inflammation in mice previously infected with the virulent Mtb K strain. In conclusion, our findings suggest that TBCM is highly immunogenic in mice and that TBCM combined with both Poly6 and alum adjuvants represents a promising vaccine platform for TB prevention and treatment.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Seo H, Kim BJ, Oh J, et al. Protection against tuberculosis by vaccination of secreted chorismate mutase (Rv1885c) combined with a hepatitis B virus (HBV)-derived peptide, Poly6, and alum adjuvants. Vaccine. 2025. PMID: 39787795. doi:10.1016/j.vaccine.2025.126710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。